DIVESTITURES, LICENSING AND OTHER ARRANGEMENTS (Tables)

6 Months Ended

Jun. 30, 2022

Acquisitions, Divestitures and Other Arrangements [Abstract]

Disposal Groups, Including Discontinued Operations

The following table summarizes the financial impact of divestitures including royalties, which are included in Other (income)/expense, net. Revenue and pretax earnings related to all divestitures were not material in all periods presented (excluding divestiture gains or losses).

	Three Months Ended June 30,
	Net Proceeds(a)				Divestiture Gains				Royalty Income
Dollars in Millions	2022		2021		2022		2021		2022		2021
Diabetes Business	$	185	$	132	$	—	$	—	$	(220)	$	(152)
Mature Products and Other	3		70		—		(11)		(1)		—
Total	$	188	$	202	$	—	$	(11)	$	(221)	$	(152)

	Six Months Ended June 30, 2022
	Net Proceeds(a)				Divestiture Gains				Royalty Income
Dollars in Millions	2022		2021		2022		2021		2022		2021
Diabetes Business	$	357	$	296	$	—	$	—	$	(390)	$	(286)
Mature Products and Other	228		86		(211)		(11)		(2)		(1)
Total	$	585	$	382	$	(211)	$	(11)	$	(392)	$	(287)

(a)    Includes royalties received subsequent to the related sale of the asset or business.

Licensing and Other Arrangements

The following table summarizes the financial impact of Keytruda* royalties, Tecentriq* royalties, upfront licensing fees and milestones for products that have not obtained commercial approval, which are included in Other (income)/expense, net.

	Three Months Ended June 30,				Six Months Ended June 30,
Dollars in Millions	2022		2021		2022		2021
Keytruda* royalties	$	(243)	$	(204)	$	(464)	$	(396)
Tecentriq* royalties	(19)		(23)		(44)		(45)
Contingent milestone income	(5)		(2)		(46)		(2)
Amortization of deferred income	(11)		(15)		(23)		(30)
Other royalties	(9)		(9)		(16)		(12)
Total	$	(287)	$	(253)	$	(593)	$	(485)